Related coverage linked through entity extraction aliases.
Jul 15, 2026
Intensity Therapeutics restarted its INVINCIBLE-4 Phase 2 trial of INT230-6 in presurgical triple-negative breast cancer, reporting 71.4% pCR with INT230-6 plus SOC versus 33% with SOC alone. 2025 cash stood at $11.9M with runway into Q2 2027.
Jul 24, 2026
Lantern Pharma's LP-284 received FDA Orphan Drug Designation for soft tissue sarcomas, while the USPTO allowed a patent for biomarker-guided use of LP-184 in multiple cancers. LP-284 showed a complete metabolic response in a Phase 1 DLBCL patient, and LP-184 demonstrated a 45% disease control rate in advanced solid tumors.
Jun 14, 2026
Patients with stage 4 lung, sarcoma, and gastro-oesophageal cancer describe their experiences with targeted therapies, chemotherapy, and immunotherapy, highlighting varying outcomes and financial challenges.
May 12, 2026
Soft tissue sarcoma pipeline activity includes 70+ companies and 75+ therapies. A phase II ADI-PEG 20 trial with gemcitabine and docetaxel was designed for sarcomas, while other 2026 studies span synovial sarcoma and unresectable advanced disease.
Apr 12, 2026
Iovance reported real-world data suggesting Amtagvi may have a best in class profile in advanced melanoma. The company posted $263.5 million in annual sales after 2024 approval, while pursuing broader use and facing regulatory and logistics risks.
Feb 26, 2026
Iovance Biotherapeutics reported Q4 2025 revenue of $87 million, beating estimates, while receiving FDA fast-track designation for lifileucel in non-small cell lung cancer and reporting strong sarcoma trial data.
